Elena Prokupets - 10 Sep 2021 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Director
Signature
/s/ Shoaib Ghias, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
10 Sep 2021
Net transactions value
-$460,985
Form type
4
Filing time
14 Sep 2021, 16:10:04 UTC
Previous filing
05 Aug 2021
Next filing
16 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Sale $61,501 -1,230 -1.4% $50.00* 87,344 10 Sep 2021 By Spouse F1, F2
transaction CCCC Common Stock Sale $66,010 -1,320 -0.22% $50.01* 591,553 10 Sep 2021 By ERP Business Holdings, LP F2, F3, F4
transaction CCCC Common Stock Sale $166,730 -3,330 -3.8% $50.07* 84,014 13 Sep 2021 By Spouse F1, F5
transaction CCCC Common Stock Sale $166,743 -3,330 -0.56% $50.07* 588,223 13 Sep 2021 By ERP Business Holdings, LP F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021.
F4 Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.54. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.